Haleon HLN.L
Haleon is a consumer health company that sells over-the-counter brands like Advil, Tums, and Sensodyne, and is seeking growth by capitalizing on the side effects of weight-loss drugs. Haleon has solid business quality (gross margin 65.57%) and an attractive valuation (FCF yield 6.0%), but its growth is weak (revenue +2.2%, earnings -4.5%) and it faces headwinds from the cold and flu season and competitive pressure.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Haleon is a consumer health company that sells over-the-counter brands like Advil, Tums, and Sensodyne, and is seeking growth by capitalizing on the side effects of weight-loss drugs. Haleon has solid business quality (gross margin 65.57%) and an attractive valuation (FCF yield 6.0%), but its growth is weak (revenue +2.2%, earnings -4.5%) and it faces headwinds from the cold and flu season and competitive pressure.
Score by category
| Category | Score |
|---|---|
| Financial health | 5.6 |
| Quality / Moat | 6.4 |
| Valuation | 6.0 |
| Growth | 3.9 |
| Dividend | 4.7 |
| Momentum | 5.1 |
| Risk & Context | 9.3 |
OVERALL SCORE: 6.0/10
Context and risks
The macro context (rates, oil, geopolitics) has no material direct impact on Haleon's consumer health business. Its rate exposure is limited (ND/EBITDA 2.61) and its demand is defensive, so no adjustments are applied through this channel.
News considered in the analysis
- Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook — Una posible rebaja de la guía de crecimiento por una temporada de resfriados débil es un riesgo material para los ingresos, aunque aún no es un hecho confirmado.
- 3 British AI Stocks With Revenue Up To £61 Billion — Listículo genérico sin información específica sobre Haleon.
- Haleon is Buying Better Shelf Space, Can the Visibility Help it Against Procter & Gamble and Colgate-Palmolive? — La inversión en mejor visibilidad en el punto de venta podría apoyar el crecimiento, pero el impacto es incierto y aún no está reflejado en el precio.
- Deutsche Bank stays bearish on Haleon as growth headwinds mount — La postura bajista de un banco de inversión refleja los vientos en contra del crecimiento, pero es una opinión que ya está parcialmente en el precio.
- Haleon Turns to Weight-Loss Drug Users for its Next U.S. Growth Opportunity — La estrategia de capitalizar los efectos secundarios de los fármacos GLP-1 es una oportunidad de crecimiento significativa, pero su éxito aún no está garantizado.
Verdict: Hold; quality and valuation offer support, but weak growth and guidance doubts limit near-term upside potential.
Main risk: The main risk is the slowdown in revenue growth, evidenced by falling earnings (-4.5%) and a potential guidance cut, which could lead to a de-rating.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →